Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|December 7, 2022
Influenza Update: Hospital Admissions Double During post-Thanksgiving Week
Author(s)Grace Halsey
Advertisement
Centers for Disease Control and Prevention director Rochelle Walensky on Monday said during a telebriefing that new admissions to the nation's hospitals doubled in the week following Thanksgiving with the increase most notable among adults aged ≥70 years.
In another sign that the 2022-2023 influenza season is off to a sobering start GoodRx reports that prescription fills for the antiviral medication Tamiflu and oseltamivir, its generic, are up by 100% over this time last year.
Scan the data snapshot here of Flu in the USA, based on the latest CDC Weekly US influenza surveillance report and other official sources.
Advertisement
Related to this article
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and promise for primary care triage to endoscopy.
ACOG's new guideline covers hormone therapy timing, neurokinin receptor antagonists, SSRIs/SNRIs, and nonpharmacologic options for menopause symptoms.
Advertisement
Advertisement
Trending on Patient Care Online
1
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
2
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
3
Long-Acting Injectable HIV PrEP: Efficacy, Safety, and Injection Reactions
4
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
5